Global Pneumococcal Vaccine

Pneumococcal Vaccine Comprehensive Study by Type (Conjugate Vaccines (PCV13), Polysaccharide Vaccines (PPSV23)), Application (Medical care, Clinics, Hospitals, Others), Sector Type (Public, Private), Vaccine Antigens (7 - Valent Vaccine, 10 - Valent Vaccine, 13 - Valent Vaccine, 23 - Valent Vaccine), Distribution Channel (Non-Governmental Organizations, Governmental Organizations), Vaccine Type (Synflorix, Prevnar 13, Pneumovax 23), End User (Adults Above 65 Years, Children Above 2 Years) Players and Region - Global Market Outlook to 2026

Pneumococcal Vaccine Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 2.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
The very first pneumococcal vaccine was made in the year 1980s. It is on the World Health Organization's List as one of the Essential Medicines, which is the safest and most effective medicines that are needed in any health system. These vaccines are normally very safe. With this conjugate vaccine, almost 10 percent of the babies develop redness at the site of injection, change in sleep, and sometimes fever. Severe kind of allergies is very rarely seen. Pneumococcal vaccines are the vaccines that fight against the bacterium streptococcus pneumoniae. The usage of these can effectively prevent some cases of pneumonia, sepsis, and meningitis. There are namely two types of pneumococcal vaccines as conjugate vaccines and polysaccharide vaccines. These are given by the means of injection either into a muscle area or just under the skin. The World Health Organization (WHO) acclaims the usage of the conjugate vaccine in routine immunization which is to be given to the children. This also includes those with that of HIV/AIDS. These vaccines, are effective for healthy adults but are not quite effective in children who are less than two years old and those having a very poor immune function. In 2013, the World Health Organization and UNICEF had issued a global plan of action for the Prevention and Control of Pneumonia and Diarrhea (GAPPD), hence marking a new chapter in the efforts towards curbing pneumonia. At present, we’re up against a very new challenge which is the COVID-19 pandemic. The coronavirus is responsible for respiratory diseases and some of those who are infected lead on to develop pneumonia. The respiratory diseases like COVID-19 are very commonly spreading by the exposure to droplets from an infected person’s sneeze or cough, or through contact with any kind of contaminated surfaces. As such, poor hygiene or sanitation and overcrowding are some of the important drivers of the transmission. Vaccines can prove out to be one of the keys to prevention. They are the global health best deal and the very first line of defense against respiratory diseases. Unlike the more affordable and available vaccines for pneumonia-like the pneumococcal vaccine which are highly crucial for freeing up the healthcare resources and at the same time enabling herd immunity. Nevertheless, the vaccines against pneumonia, like the pneumococcal vaccine do not exactly provide any sort of protection against COVID-19. Although these vaccines are not very effective against the COVID-19, the vaccination against the prevention of respiratory illnesses is highly recommended for the protection of health. Due to less consumption and the need for the vaccines the market is likely to grow at a very slow rate. The global pneumonia vaccines market was valued at USD 5230 million in 2019 and is expected to reach USD 5924.56 million by 2025, growing at a CAGR of 2.1 % from 2019 to 2025.The research analyst at AMA estimates Pneumococcal Vaccine market to grow at a compounded annual growth rate of 2.1%

Segment Analysis
AMA Research have segmented the market of Global Pneumococcal Vaccine market by Type, Application and Region. On the basis of Type, Conjugate PCV13 are dominating the market in the year 2020 where as Polysaccharide PPV23 stood as second largest market share.

On the basis of geography, the market of Pneumococcal Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Trend
The Rising Awareness among the Patients about Pneumococcal Vaccines and Its Benefits Has Boosted the Pneumococcal Vaccines Market and The Growing Trend of Easier Access to Healthcare Facilities and the Provision of Low-Cost Pneumonia Vaccines Has Also Attracted Several Consumers Causing the Market’s Growth

Market Drivers
The Developing Countries Are Progressively Investing in the Manufacturing of Vaccines That is leading to an Expansion in the Global Pneumococcal Vaccines Market and There Are Several Initiatives Taken By the Governments for Prevention of Pneumonia and Has Hence Supported in the Expansion of the Market

Opportunities
Continuous Research and Development Activities and Great Initiatives Taken By the Governments Would Provide New Opportunities for the Market and New Growth Opportunities for the Global Pneumococcal Vaccines Market Have Been Created With the Development of the Protein Vaccines for Pneumococcal Diseases

Restraints
  • The Higher Costs That Are Associated With the Manufacturing of the Vaccines Can Cause a Hindrance to the Growth of the Market


In addition to the aforementioned factor, The Developing Countries Are Progressively Investing in the Manufacturing of Vaccines That is leading to an Expansion in the Global Pneumococcal Vaccines Market is expected to propel the growth of the market over the forecast period.

Competitive Landscape
In the Pneumococcal Vaccine Market, it has been observed that most of the companies are upgrading or introducing innovative products. They rely on strategies such as mergers & acquisitions, product development, geographical expansion, technological innovation and sourcing strategies to enhance their market share.
The key Players profiled in the study are GlaxoSmithKline (United Kingdom), Novartis (Switzerland), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Sanofi Pasteur (France), Protein Sciences Corporation (United States), Seqirus (United States), LG Chem Ltd. (South Korea), Walvax Biotechnology Co., Ltd. (China), Panacea Biotec (India), Pnuvax Incorporated (Canada) and Serum Institute of India Pvt. Ltd. (India). A lot of Asia Pacific players are profiled in the research study indicating a strong market dependence.

Report Objectives / Segmentation Covered

By Type
  • Conjugate Vaccines (PCV13)
  • Polysaccharide Vaccines (PPSV23)
By Application
  • Medical care
  • Clinics
  • Hospitals
  • Others
By Sector Type
  • Public
  • Private

By Vaccine Antigens
  • 7 - Valent Vaccine
  • 10 - Valent Vaccine
  • 13 - Valent Vaccine
  • 23 - Valent Vaccine

By Distribution Channel
  • Non-Governmental Organizations
  • Governmental Organizations

By Vaccine Type
  • Synflorix
  • Prevnar 13
  • Pneumovax 23

By End User
  • Adults Above 65 Years
  • Children Above 2 Years

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Developing Countries Are Progressively Investing in the Manufacturing of Vaccines That is leading to an Expansion in the Global Pneumococcal Vaccines Market
      • 3.2.2. There Are Several Initiatives Taken By the Governments for Prevention of Pneumonia and Has Hence Supported in the Expansion of the Market
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Older Population Regarding the Vaccines
    • 3.4. Market Trends
      • 3.4.1. The Rising Awareness among the Patients about Pneumococcal Vaccines and Its Benefits Has Boosted the Pneumococcal Vaccines Market
      • 3.4.2. The Growing Trend of Easier Access to Healthcare Facilities and the Provision of Low-Cost Pneumonia Vaccines Has Also Attracted Several Consumers Causing the Market’s Growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pneumococcal Vaccine, by Type, Application, Sector Type, Vaccine Antigens, Distribution Channel, Vaccine Type, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pneumococcal Vaccine (Value)
      • 5.2.1. Global Pneumococcal Vaccine by: Type (Value)
        • 5.2.1.1. Conjugate Vaccines (PCV13)
        • 5.2.1.2. Polysaccharide Vaccines (PPSV23)
      • 5.2.2. Global Pneumococcal Vaccine by: Application (Value)
        • 5.2.2.1. Medical care
        • 5.2.2.2. Clinics
        • 5.2.2.3. Hospitals
        • 5.2.2.4. Others
      • 5.2.3. Global Pneumococcal Vaccine by: Sector Type (Value)
        • 5.2.3.1. Public
        • 5.2.3.2. Private
      • 5.2.4. Global Pneumococcal Vaccine by: Vaccine Antigens (Value)
        • 5.2.4.1. 7 - Valent Vaccine
        • 5.2.4.2. 10 - Valent Vaccine
        • 5.2.4.3. 13 - Valent Vaccine
        • 5.2.4.4. 23 - Valent Vaccine
      • 5.2.5. Global Pneumococcal Vaccine by: Distribution Channel (Value)
        • 5.2.5.1. Non-Governmental Organizations
        • 5.2.5.2. Governmental Organizations
      • 5.2.6. Global Pneumococcal Vaccine by: Vaccine Type (Value)
        • 5.2.6.1. Synflorix
        • 5.2.6.2. Prevnar 13
        • 5.2.6.3. Pneumovax 23
      • 5.2.7. Global Pneumococcal Vaccine by: End User (Value)
        • 5.2.7.1. Adults Above 65 Years
        • 5.2.7.2. Children Above 2 Years
      • 5.2.8. Global Pneumococcal Vaccine Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Pneumococcal Vaccine (Volume)
      • 5.3.1. Global Pneumococcal Vaccine by: Type (Volume)
        • 5.3.1.1. Conjugate Vaccines (PCV13)
        • 5.3.1.2. Polysaccharide Vaccines (PPSV23)
      • 5.3.2. Global Pneumococcal Vaccine by: Application (Volume)
        • 5.3.2.1. Medical care
        • 5.3.2.2. Clinics
        • 5.3.2.3. Hospitals
        • 5.3.2.4. Others
      • 5.3.3. Global Pneumococcal Vaccine by: Sector Type (Volume)
        • 5.3.3.1. Public
        • 5.3.3.2. Private
      • 5.3.4. Global Pneumococcal Vaccine by: Vaccine Antigens (Volume)
        • 5.3.4.1. 7 - Valent Vaccine
        • 5.3.4.2. 10 - Valent Vaccine
        • 5.3.4.3. 13 - Valent Vaccine
        • 5.3.4.4. 23 - Valent Vaccine
      • 5.3.5. Global Pneumococcal Vaccine by: Distribution Channel (Volume)
        • 5.3.5.1. Non-Governmental Organizations
        • 5.3.5.2. Governmental Organizations
      • 5.3.6. Global Pneumococcal Vaccine by: Vaccine Type (Volume)
        • 5.3.6.1. Synflorix
        • 5.3.6.2. Prevnar 13
        • 5.3.6.3. Pneumovax 23
      • 5.3.7. Global Pneumococcal Vaccine by: End User (Volume)
        • 5.3.7.1. Adults Above 65 Years
        • 5.3.7.2. Children Above 2 Years
      • 5.3.8. Global Pneumococcal Vaccine Region
        • 5.3.8.1. South America
          • 5.3.8.1.1. Brazil
          • 5.3.8.1.2. Argentina
          • 5.3.8.1.3. Rest of South America
        • 5.3.8.2. Asia Pacific
          • 5.3.8.2.1. China
          • 5.3.8.2.2. Japan
          • 5.3.8.2.3. India
          • 5.3.8.2.4. South Korea
          • 5.3.8.2.5. Taiwan
          • 5.3.8.2.6. Australia
          • 5.3.8.2.7. Rest of Asia-Pacific
        • 5.3.8.3. Europe
          • 5.3.8.3.1. Germany
          • 5.3.8.3.2. France
          • 5.3.8.3.3. Italy
          • 5.3.8.3.4. United Kingdom
          • 5.3.8.3.5. Netherlands
          • 5.3.8.3.6. Rest of Europe
        • 5.3.8.4. MEA
          • 5.3.8.4.1. Middle East
          • 5.3.8.4.2. Africa
        • 5.3.8.5. North America
          • 5.3.8.5.1. United States
          • 5.3.8.5.2. Canada
          • 5.3.8.5.3. Mexico
    • 5.4. Global Pneumococcal Vaccine (Price)
      • 5.4.1. Global Pneumococcal Vaccine by: Type (Price)
  • 6. Pneumococcal Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi Pasteur (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Protein Sciences Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Seqirus (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LG Chem Ltd. (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Walvax Biotechnology Co., Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Panacea Biotec (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Pnuvax Incorporated (Canada)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Serum Institute of India Pvt. Ltd. (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Pneumococcal Vaccine Sale, by Type, Application, Sector Type, Vaccine Antigens, Distribution Channel, Vaccine Type, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pneumococcal Vaccine (Value)
      • 7.2.1. Global Pneumococcal Vaccine by: Type (Value)
        • 7.2.1.1. Conjugate Vaccines (PCV13)
        • 7.2.1.2. Polysaccharide Vaccines (PPSV23)
      • 7.2.2. Global Pneumococcal Vaccine by: Application (Value)
        • 7.2.2.1. Medical care
        • 7.2.2.2. Clinics
        • 7.2.2.3. Hospitals
        • 7.2.2.4. Others
      • 7.2.3. Global Pneumococcal Vaccine by: Sector Type (Value)
        • 7.2.3.1. Public
        • 7.2.3.2. Private
      • 7.2.4. Global Pneumococcal Vaccine by: Vaccine Antigens (Value)
        • 7.2.4.1. 7 - Valent Vaccine
        • 7.2.4.2. 10 - Valent Vaccine
        • 7.2.4.3. 13 - Valent Vaccine
        • 7.2.4.4. 23 - Valent Vaccine
      • 7.2.5. Global Pneumococcal Vaccine by: Distribution Channel (Value)
        • 7.2.5.1. Non-Governmental Organizations
        • 7.2.5.2. Governmental Organizations
      • 7.2.6. Global Pneumococcal Vaccine by: Vaccine Type (Value)
        • 7.2.6.1. Synflorix
        • 7.2.6.2. Prevnar 13
        • 7.2.6.3. Pneumovax 23
      • 7.2.7. Global Pneumococcal Vaccine by: End User (Value)
        • 7.2.7.1. Adults Above 65 Years
        • 7.2.7.2. Children Above 2 Years
      • 7.2.8. Global Pneumococcal Vaccine Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Pneumococcal Vaccine (Volume)
      • 7.3.1. Global Pneumococcal Vaccine by: Type (Volume)
        • 7.3.1.1. Conjugate Vaccines (PCV13)
        • 7.3.1.2. Polysaccharide Vaccines (PPSV23)
      • 7.3.2. Global Pneumococcal Vaccine by: Application (Volume)
        • 7.3.2.1. Medical care
        • 7.3.2.2. Clinics
        • 7.3.2.3. Hospitals
        • 7.3.2.4. Others
      • 7.3.3. Global Pneumococcal Vaccine by: Sector Type (Volume)
        • 7.3.3.1. Public
        • 7.3.3.2. Private
      • 7.3.4. Global Pneumococcal Vaccine by: Vaccine Antigens (Volume)
        • 7.3.4.1. 7 - Valent Vaccine
        • 7.3.4.2. 10 - Valent Vaccine
        • 7.3.4.3. 13 - Valent Vaccine
        • 7.3.4.4. 23 - Valent Vaccine
      • 7.3.5. Global Pneumococcal Vaccine by: Distribution Channel (Volume)
        • 7.3.5.1. Non-Governmental Organizations
        • 7.3.5.2. Governmental Organizations
      • 7.3.6. Global Pneumococcal Vaccine by: Vaccine Type (Volume)
        • 7.3.6.1. Synflorix
        • 7.3.6.2. Prevnar 13
        • 7.3.6.3. Pneumovax 23
      • 7.3.7. Global Pneumococcal Vaccine by: End User (Volume)
        • 7.3.7.1. Adults Above 65 Years
        • 7.3.7.2. Children Above 2 Years
      • 7.3.8. Global Pneumococcal Vaccine Region
        • 7.3.8.1. South America
          • 7.3.8.1.1. Brazil
          • 7.3.8.1.2. Argentina
          • 7.3.8.1.3. Rest of South America
        • 7.3.8.2. Asia Pacific
          • 7.3.8.2.1. China
          • 7.3.8.2.2. Japan
          • 7.3.8.2.3. India
          • 7.3.8.2.4. South Korea
          • 7.3.8.2.5. Taiwan
          • 7.3.8.2.6. Australia
          • 7.3.8.2.7. Rest of Asia-Pacific
        • 7.3.8.3. Europe
          • 7.3.8.3.1. Germany
          • 7.3.8.3.2. France
          • 7.3.8.3.3. Italy
          • 7.3.8.3.4. United Kingdom
          • 7.3.8.3.5. Netherlands
          • 7.3.8.3.6. Rest of Europe
        • 7.3.8.4. MEA
          • 7.3.8.4.1. Middle East
          • 7.3.8.4.2. Africa
        • 7.3.8.5. North America
          • 7.3.8.5.1. United States
          • 7.3.8.5.2. Canada
          • 7.3.8.5.3. Mexico
    • 7.4. Global Pneumococcal Vaccine (Price)
      • 7.4.1. Global Pneumococcal Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pneumococcal Vaccine: by Type(USD Million)
  • Table 2. Pneumococcal Vaccine Conjugate Vaccines (PCV13) , by Region USD Million (2015-2020)
  • Table 3. Pneumococcal Vaccine Polysaccharide Vaccines (PPSV23) , by Region USD Million (2015-2020)
  • Table 4. Pneumococcal Vaccine: by Application(USD Million)
  • Table 5. Pneumococcal Vaccine Medical care , by Region USD Million (2015-2020)
  • Table 6. Pneumococcal Vaccine Clinics , by Region USD Million (2015-2020)
  • Table 7. Pneumococcal Vaccine Hospitals , by Region USD Million (2015-2020)
  • Table 8. Pneumococcal Vaccine Others , by Region USD Million (2015-2020)
  • Table 9. Pneumococcal Vaccine: by Sector Type(USD Million)
  • Table 10. Pneumococcal Vaccine Public , by Region USD Million (2015-2020)
  • Table 11. Pneumococcal Vaccine Private , by Region USD Million (2015-2020)
  • Table 12. Pneumococcal Vaccine: by Vaccine Antigens(USD Million)
  • Table 13. Pneumococcal Vaccine 7 - Valent Vaccine , by Region USD Million (2015-2020)
  • Table 14. Pneumococcal Vaccine 10 - Valent Vaccine , by Region USD Million (2015-2020)
  • Table 15. Pneumococcal Vaccine 13 - Valent Vaccine , by Region USD Million (2015-2020)
  • Table 16. Pneumococcal Vaccine 23 - Valent Vaccine , by Region USD Million (2015-2020)
  • Table 17. Pneumococcal Vaccine: by Distribution Channel(USD Million)
  • Table 18. Pneumococcal Vaccine Non-Governmental Organizations , by Region USD Million (2015-2020)
  • Table 19. Pneumococcal Vaccine Governmental Organizations , by Region USD Million (2015-2020)
  • Table 20. Pneumococcal Vaccine: by Vaccine Type(USD Million)
  • Table 21. Pneumococcal Vaccine Synflorix , by Region USD Million (2015-2020)
  • Table 22. Pneumococcal Vaccine Prevnar 13 , by Region USD Million (2015-2020)
  • Table 23. Pneumococcal Vaccine Pneumovax 23 , by Region USD Million (2015-2020)
  • Table 24. Pneumococcal Vaccine: by End User(USD Million)
  • Table 25. Pneumococcal Vaccine Adults Above 65 Years , by Region USD Million (2015-2020)
  • Table 26. Pneumococcal Vaccine Children Above 2 Years , by Region USD Million (2015-2020)
  • Table 27. South America Pneumococcal Vaccine, by Country USD Million (2015-2020)
  • Table 28. South America Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 29. South America Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 30. South America Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 31. South America Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 32. South America Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 33. South America Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 34. South America Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 35. Brazil Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 36. Brazil Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 37. Brazil Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 38. Brazil Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 39. Brazil Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 40. Brazil Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 41. Brazil Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 42. Argentina Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 43. Argentina Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 44. Argentina Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 45. Argentina Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 46. Argentina Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 47. Argentina Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 48. Argentina Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 49. Rest of South America Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 50. Rest of South America Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 51. Rest of South America Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 52. Rest of South America Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 53. Rest of South America Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 54. Rest of South America Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 55. Rest of South America Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 56. Asia Pacific Pneumococcal Vaccine, by Country USD Million (2015-2020)
  • Table 57. Asia Pacific Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 58. Asia Pacific Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 59. Asia Pacific Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 60. Asia Pacific Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 61. Asia Pacific Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 62. Asia Pacific Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 63. Asia Pacific Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 64. China Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 65. China Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 66. China Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 67. China Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 68. China Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 69. China Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 70. China Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 71. Japan Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 72. Japan Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 73. Japan Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 74. Japan Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 75. Japan Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 76. Japan Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 77. Japan Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 78. India Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 79. India Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 80. India Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 81. India Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 82. India Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 83. India Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 84. India Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 85. South Korea Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 86. South Korea Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 87. South Korea Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 88. South Korea Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 89. South Korea Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 90. South Korea Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 91. South Korea Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 92. Taiwan Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 93. Taiwan Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 94. Taiwan Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 95. Taiwan Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 96. Taiwan Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 97. Taiwan Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 98. Taiwan Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 99. Australia Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 100. Australia Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 101. Australia Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 102. Australia Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 103. Australia Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 104. Australia Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 105. Australia Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 106. Rest of Asia-Pacific Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 107. Rest of Asia-Pacific Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 108. Rest of Asia-Pacific Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 109. Rest of Asia-Pacific Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 110. Rest of Asia-Pacific Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 111. Rest of Asia-Pacific Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 112. Rest of Asia-Pacific Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 113. Europe Pneumococcal Vaccine, by Country USD Million (2015-2020)
  • Table 114. Europe Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 115. Europe Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 116. Europe Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 117. Europe Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 118. Europe Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 119. Europe Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 120. Europe Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 121. Germany Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 122. Germany Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 123. Germany Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 124. Germany Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 125. Germany Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 126. Germany Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 127. Germany Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 128. France Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 129. France Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 130. France Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 131. France Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 132. France Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 133. France Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 134. France Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 135. Italy Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 136. Italy Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 137. Italy Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 138. Italy Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 139. Italy Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 140. Italy Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 141. Italy Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 142. United Kingdom Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 143. United Kingdom Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 144. United Kingdom Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 145. United Kingdom Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 146. United Kingdom Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 147. United Kingdom Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 148. United Kingdom Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 149. Netherlands Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 150. Netherlands Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 151. Netherlands Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 152. Netherlands Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 153. Netherlands Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 154. Netherlands Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 155. Netherlands Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 156. Rest of Europe Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 157. Rest of Europe Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 158. Rest of Europe Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 159. Rest of Europe Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 160. Rest of Europe Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 161. Rest of Europe Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 162. Rest of Europe Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 163. MEA Pneumococcal Vaccine, by Country USD Million (2015-2020)
  • Table 164. MEA Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 165. MEA Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 166. MEA Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 167. MEA Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 168. MEA Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 169. MEA Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 170. MEA Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 171. Middle East Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 172. Middle East Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 173. Middle East Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 174. Middle East Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 175. Middle East Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 176. Middle East Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 177. Middle East Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 178. Africa Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 179. Africa Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 180. Africa Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 181. Africa Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 182. Africa Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 183. Africa Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 184. Africa Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 185. North America Pneumococcal Vaccine, by Country USD Million (2015-2020)
  • Table 186. North America Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 187. North America Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 188. North America Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 189. North America Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 190. North America Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 191. North America Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 192. North America Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 193. United States Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 194. United States Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 195. United States Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 196. United States Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 197. United States Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 198. United States Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 199. United States Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 200. Canada Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 201. Canada Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 202. Canada Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 203. Canada Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 204. Canada Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 205. Canada Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 206. Canada Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 207. Mexico Pneumococcal Vaccine, by Type USD Million (2015-2020)
  • Table 208. Mexico Pneumococcal Vaccine, by Application USD Million (2015-2020)
  • Table 209. Mexico Pneumococcal Vaccine, by Sector Type USD Million (2015-2020)
  • Table 210. Mexico Pneumococcal Vaccine, by Vaccine Antigens USD Million (2015-2020)
  • Table 211. Mexico Pneumococcal Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 212. Mexico Pneumococcal Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 213. Mexico Pneumococcal Vaccine, by End User USD Million (2015-2020)
  • Table 214. Pneumococcal Vaccine Sales: by Type(Tons)
  • Table 215. Pneumococcal Vaccine Sales Conjugate Vaccines (PCV13) , by Region Tons (2015-2020)
  • Table 216. Pneumococcal Vaccine Sales Polysaccharide Vaccines (PPSV23) , by Region Tons (2015-2020)
  • Table 217. Pneumococcal Vaccine Sales: by Application(Tons)
  • Table 218. Pneumococcal Vaccine Sales Medical care , by Region Tons (2015-2020)
  • Table 219. Pneumococcal Vaccine Sales Clinics , by Region Tons (2015-2020)
  • Table 220. Pneumococcal Vaccine Sales Hospitals , by Region Tons (2015-2020)
  • Table 221. Pneumococcal Vaccine Sales Others , by Region Tons (2015-2020)
  • Table 222. Pneumococcal Vaccine Sales: by Sector Type(Tons)
  • Table 223. Pneumococcal Vaccine Sales Public , by Region Tons (2015-2020)
  • Table 224. Pneumococcal Vaccine Sales Private , by Region Tons (2015-2020)
  • Table 225. Pneumococcal Vaccine Sales: by Vaccine Antigens(Tons)
  • Table 226. Pneumococcal Vaccine Sales 7 - Valent Vaccine , by Region Tons (2015-2020)
  • Table 227. Pneumococcal Vaccine Sales 10 - Valent Vaccine , by Region Tons (2015-2020)
  • Table 228. Pneumococcal Vaccine Sales 13 - Valent Vaccine , by Region Tons (2015-2020)
  • Table 229. Pneumococcal Vaccine Sales 23 - Valent Vaccine , by Region Tons (2015-2020)
  • Table 230. Pneumococcal Vaccine Sales: by Distribution Channel(Tons)
  • Table 231. Pneumococcal Vaccine Sales Non-Governmental Organizations , by Region Tons (2015-2020)
  • Table 232. Pneumococcal Vaccine Sales Governmental Organizations , by Region Tons (2015-2020)
  • Table 233. Pneumococcal Vaccine Sales: by Vaccine Type(Tons)
  • Table 234. Pneumococcal Vaccine Sales Synflorix , by Region Tons (2015-2020)
  • Table 235. Pneumococcal Vaccine Sales Prevnar 13 , by Region Tons (2015-2020)
  • Table 236. Pneumococcal Vaccine Sales Pneumovax 23 , by Region Tons (2015-2020)
  • Table 237. Pneumococcal Vaccine Sales: by End User(Tons)
  • Table 238. Pneumococcal Vaccine Sales Adults Above 65 Years , by Region Tons (2015-2020)
  • Table 239. Pneumococcal Vaccine Sales Children Above 2 Years , by Region Tons (2015-2020)
  • Table 240. South America Pneumococcal Vaccine Sales, by Country Tons (2015-2020)
  • Table 241. South America Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 242. South America Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 243. South America Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 244. South America Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 245. South America Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 246. South America Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 247. South America Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 248. Brazil Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 249. Brazil Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 250. Brazil Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 251. Brazil Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 252. Brazil Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 253. Brazil Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 254. Brazil Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 255. Argentina Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 256. Argentina Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 257. Argentina Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 258. Argentina Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 259. Argentina Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 260. Argentina Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 261. Argentina Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 262. Rest of South America Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 263. Rest of South America Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 264. Rest of South America Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 265. Rest of South America Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 266. Rest of South America Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 267. Rest of South America Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 268. Rest of South America Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 269. Asia Pacific Pneumococcal Vaccine Sales, by Country Tons (2015-2020)
  • Table 270. Asia Pacific Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 271. Asia Pacific Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 272. Asia Pacific Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 273. Asia Pacific Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 274. Asia Pacific Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 275. Asia Pacific Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 276. Asia Pacific Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 277. China Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 278. China Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 279. China Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 280. China Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 281. China Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 282. China Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 283. China Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 284. Japan Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 285. Japan Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 286. Japan Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 287. Japan Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 288. Japan Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 289. Japan Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 290. Japan Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 291. India Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 292. India Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 293. India Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 294. India Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 295. India Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 296. India Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 297. India Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 298. South Korea Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 299. South Korea Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 300. South Korea Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 301. South Korea Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 302. South Korea Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 303. South Korea Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 304. South Korea Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 305. Taiwan Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 306. Taiwan Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 307. Taiwan Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 308. Taiwan Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 309. Taiwan Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 310. Taiwan Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 311. Taiwan Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 312. Australia Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 313. Australia Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 314. Australia Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 315. Australia Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 316. Australia Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 317. Australia Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 318. Australia Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 319. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 320. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 321. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 322. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 323. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 324. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 325. Rest of Asia-Pacific Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 326. Europe Pneumococcal Vaccine Sales, by Country Tons (2015-2020)
  • Table 327. Europe Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 328. Europe Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 329. Europe Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 330. Europe Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 331. Europe Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 332. Europe Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 333. Europe Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 334. Germany Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 335. Germany Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 336. Germany Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 337. Germany Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 338. Germany Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 339. Germany Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 340. Germany Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 341. France Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 342. France Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 343. France Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 344. France Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 345. France Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 346. France Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 347. France Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 348. Italy Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 349. Italy Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 350. Italy Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 351. Italy Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 352. Italy Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 353. Italy Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 354. Italy Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 355. United Kingdom Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 356. United Kingdom Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 357. United Kingdom Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 358. United Kingdom Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 359. United Kingdom Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 360. United Kingdom Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 361. United Kingdom Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 362. Netherlands Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 363. Netherlands Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 364. Netherlands Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 365. Netherlands Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 366. Netherlands Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 367. Netherlands Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 368. Netherlands Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 369. Rest of Europe Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 370. Rest of Europe Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 371. Rest of Europe Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 372. Rest of Europe Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 373. Rest of Europe Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 374. Rest of Europe Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 375. Rest of Europe Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 376. MEA Pneumococcal Vaccine Sales, by Country Tons (2015-2020)
  • Table 377. MEA Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 378. MEA Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 379. MEA Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 380. MEA Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 381. MEA Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 382. MEA Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 383. MEA Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 384. Middle East Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 385. Middle East Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 386. Middle East Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 387. Middle East Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 388. Middle East Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 389. Middle East Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 390. Middle East Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 391. Africa Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 392. Africa Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 393. Africa Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 394. Africa Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 395. Africa Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 396. Africa Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 397. Africa Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 398. North America Pneumococcal Vaccine Sales, by Country Tons (2015-2020)
  • Table 399. North America Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 400. North America Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 401. North America Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 402. North America Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 403. North America Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 404. North America Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 405. North America Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 406. United States Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 407. United States Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 408. United States Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 409. United States Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 410. United States Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 411. United States Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 412. United States Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 413. Canada Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 414. Canada Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 415. Canada Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 416. Canada Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 417. Canada Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 418. Canada Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 419. Canada Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 420. Mexico Pneumococcal Vaccine Sales, by Type Tons (2015-2020)
  • Table 421. Mexico Pneumococcal Vaccine Sales, by Application Tons (2015-2020)
  • Table 422. Mexico Pneumococcal Vaccine Sales, by Sector Type Tons (2015-2020)
  • Table 423. Mexico Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2015-2020)
  • Table 424. Mexico Pneumococcal Vaccine Sales, by Distribution Channel Tons (2015-2020)
  • Table 425. Mexico Pneumococcal Vaccine Sales, by Vaccine Type Tons (2015-2020)
  • Table 426. Mexico Pneumococcal Vaccine Sales, by End User Tons (2015-2020)
  • Table 427. Pneumococcal Vaccine: by Type(USD/Units)
  • Table 428. Company Basic Information, Sales Area and Its Competitors
  • Table 429. Company Basic Information, Sales Area and Its Competitors
  • Table 430. Company Basic Information, Sales Area and Its Competitors
  • Table 431. Company Basic Information, Sales Area and Its Competitors
  • Table 432. Company Basic Information, Sales Area and Its Competitors
  • Table 433. Company Basic Information, Sales Area and Its Competitors
  • Table 434. Company Basic Information, Sales Area and Its Competitors
  • Table 435. Company Basic Information, Sales Area and Its Competitors
  • Table 436. Company Basic Information, Sales Area and Its Competitors
  • Table 437. Company Basic Information, Sales Area and Its Competitors
  • Table 438. Company Basic Information, Sales Area and Its Competitors
  • Table 439. Company Basic Information, Sales Area and Its Competitors
  • Table 440. Pneumococcal Vaccine: by Type(USD Million)
  • Table 441. Pneumococcal Vaccine Conjugate Vaccines (PCV13) , by Region USD Million (2021-2026)
  • Table 442. Pneumococcal Vaccine Polysaccharide Vaccines (PPSV23) , by Region USD Million (2021-2026)
  • Table 443. Pneumococcal Vaccine: by Application(USD Million)
  • Table 444. Pneumococcal Vaccine Medical care , by Region USD Million (2021-2026)
  • Table 445. Pneumococcal Vaccine Clinics , by Region USD Million (2021-2026)
  • Table 446. Pneumococcal Vaccine Hospitals , by Region USD Million (2021-2026)
  • Table 447. Pneumococcal Vaccine Others , by Region USD Million (2021-2026)
  • Table 448. Pneumococcal Vaccine: by Sector Type(USD Million)
  • Table 449. Pneumococcal Vaccine Public , by Region USD Million (2021-2026)
  • Table 450. Pneumococcal Vaccine Private , by Region USD Million (2021-2026)
  • Table 451. Pneumococcal Vaccine: by Vaccine Antigens(USD Million)
  • Table 452. Pneumococcal Vaccine 7 - Valent Vaccine , by Region USD Million (2021-2026)
  • Table 453. Pneumococcal Vaccine 10 - Valent Vaccine , by Region USD Million (2021-2026)
  • Table 454. Pneumococcal Vaccine 13 - Valent Vaccine , by Region USD Million (2021-2026)
  • Table 455. Pneumococcal Vaccine 23 - Valent Vaccine , by Region USD Million (2021-2026)
  • Table 456. Pneumococcal Vaccine: by Distribution Channel(USD Million)
  • Table 457. Pneumococcal Vaccine Non-Governmental Organizations , by Region USD Million (2021-2026)
  • Table 458. Pneumococcal Vaccine Governmental Organizations , by Region USD Million (2021-2026)
  • Table 459. Pneumococcal Vaccine: by Vaccine Type(USD Million)
  • Table 460. Pneumococcal Vaccine Synflorix , by Region USD Million (2021-2026)
  • Table 461. Pneumococcal Vaccine Prevnar 13 , by Region USD Million (2021-2026)
  • Table 462. Pneumococcal Vaccine Pneumovax 23 , by Region USD Million (2021-2026)
  • Table 463. Pneumococcal Vaccine: by End User(USD Million)
  • Table 464. Pneumococcal Vaccine Adults Above 65 Years , by Region USD Million (2021-2026)
  • Table 465. Pneumococcal Vaccine Children Above 2 Years , by Region USD Million (2021-2026)
  • Table 466. South America Pneumococcal Vaccine, by Country USD Million (2021-2026)
  • Table 467. South America Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 468. South America Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 469. South America Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 470. South America Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 471. South America Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 472. South America Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 473. South America Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 474. Brazil Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 475. Brazil Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 476. Brazil Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 477. Brazil Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 478. Brazil Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 479. Brazil Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 480. Brazil Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 481. Argentina Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 482. Argentina Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 483. Argentina Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 484. Argentina Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 485. Argentina Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 486. Argentina Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 487. Argentina Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 488. Rest of South America Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 489. Rest of South America Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 490. Rest of South America Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 491. Rest of South America Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 492. Rest of South America Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 493. Rest of South America Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 494. Rest of South America Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 495. Asia Pacific Pneumococcal Vaccine, by Country USD Million (2021-2026)
  • Table 496. Asia Pacific Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 497. Asia Pacific Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 498. Asia Pacific Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 499. Asia Pacific Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 500. Asia Pacific Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 501. Asia Pacific Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 502. Asia Pacific Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 503. China Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 504. China Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 505. China Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 506. China Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 507. China Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 508. China Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 509. China Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 510. Japan Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 511. Japan Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 512. Japan Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 513. Japan Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 514. Japan Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 515. Japan Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 516. Japan Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 517. India Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 518. India Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 519. India Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 520. India Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 521. India Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 522. India Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 523. India Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 524. South Korea Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 525. South Korea Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 526. South Korea Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 527. South Korea Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 528. South Korea Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 529. South Korea Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 530. South Korea Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 531. Taiwan Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 532. Taiwan Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 533. Taiwan Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 534. Taiwan Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 535. Taiwan Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 536. Taiwan Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 537. Taiwan Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 538. Australia Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 539. Australia Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 540. Australia Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 541. Australia Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 542. Australia Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 543. Australia Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 544. Australia Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 545. Rest of Asia-Pacific Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 546. Rest of Asia-Pacific Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 547. Rest of Asia-Pacific Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 548. Rest of Asia-Pacific Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 549. Rest of Asia-Pacific Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 550. Rest of Asia-Pacific Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 551. Rest of Asia-Pacific Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 552. Europe Pneumococcal Vaccine, by Country USD Million (2021-2026)
  • Table 553. Europe Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 554. Europe Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 555. Europe Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 556. Europe Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 557. Europe Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 558. Europe Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 559. Europe Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 560. Germany Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 561. Germany Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 562. Germany Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 563. Germany Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 564. Germany Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 565. Germany Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 566. Germany Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 567. France Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 568. France Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 569. France Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 570. France Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 571. France Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 572. France Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 573. France Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 574. Italy Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 575. Italy Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 576. Italy Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 577. Italy Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 578. Italy Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 579. Italy Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 580. Italy Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 581. United Kingdom Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 582. United Kingdom Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 583. United Kingdom Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 584. United Kingdom Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 585. United Kingdom Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 586. United Kingdom Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 587. United Kingdom Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 588. Netherlands Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 589. Netherlands Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 590. Netherlands Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 591. Netherlands Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 592. Netherlands Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 593. Netherlands Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 594. Netherlands Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 595. Rest of Europe Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 596. Rest of Europe Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 597. Rest of Europe Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 598. Rest of Europe Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 599. Rest of Europe Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 600. Rest of Europe Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 601. Rest of Europe Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 602. MEA Pneumococcal Vaccine, by Country USD Million (2021-2026)
  • Table 603. MEA Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 604. MEA Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 605. MEA Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 606. MEA Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 607. MEA Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 608. MEA Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 609. MEA Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 610. Middle East Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 611. Middle East Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 612. Middle East Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 613. Middle East Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 614. Middle East Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 615. Middle East Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 616. Middle East Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 617. Africa Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 618. Africa Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 619. Africa Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 620. Africa Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 621. Africa Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 622. Africa Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 623. Africa Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 624. North America Pneumococcal Vaccine, by Country USD Million (2021-2026)
  • Table 625. North America Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 626. North America Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 627. North America Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 628. North America Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 629. North America Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 630. North America Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 631. North America Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 632. United States Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 633. United States Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 634. United States Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 635. United States Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 636. United States Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 637. United States Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 638. United States Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 639. Canada Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 640. Canada Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 641. Canada Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 642. Canada Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 643. Canada Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 644. Canada Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 645. Canada Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 646. Mexico Pneumococcal Vaccine, by Type USD Million (2021-2026)
  • Table 647. Mexico Pneumococcal Vaccine, by Application USD Million (2021-2026)
  • Table 648. Mexico Pneumococcal Vaccine, by Sector Type USD Million (2021-2026)
  • Table 649. Mexico Pneumococcal Vaccine, by Vaccine Antigens USD Million (2021-2026)
  • Table 650. Mexico Pneumococcal Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 651. Mexico Pneumococcal Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 652. Mexico Pneumococcal Vaccine, by End User USD Million (2021-2026)
  • Table 653. Pneumococcal Vaccine Sales: by Type(Tons)
  • Table 654. Pneumococcal Vaccine Sales Conjugate Vaccines (PCV13) , by Region Tons (2021-2026)
  • Table 655. Pneumococcal Vaccine Sales Polysaccharide Vaccines (PPSV23) , by Region Tons (2021-2026)
  • Table 656. Pneumococcal Vaccine Sales: by Application(Tons)
  • Table 657. Pneumococcal Vaccine Sales Medical care , by Region Tons (2021-2026)
  • Table 658. Pneumococcal Vaccine Sales Clinics , by Region Tons (2021-2026)
  • Table 659. Pneumococcal Vaccine Sales Hospitals , by Region Tons (2021-2026)
  • Table 660. Pneumococcal Vaccine Sales Others , by Region Tons (2021-2026)
  • Table 661. Pneumococcal Vaccine Sales: by Sector Type(Tons)
  • Table 662. Pneumococcal Vaccine Sales Public , by Region Tons (2021-2026)
  • Table 663. Pneumococcal Vaccine Sales Private , by Region Tons (2021-2026)
  • Table 664. Pneumococcal Vaccine Sales: by Vaccine Antigens(Tons)
  • Table 665. Pneumococcal Vaccine Sales 7 - Valent Vaccine , by Region Tons (2021-2026)
  • Table 666. Pneumococcal Vaccine Sales 10 - Valent Vaccine , by Region Tons (2021-2026)
  • Table 667. Pneumococcal Vaccine Sales 13 - Valent Vaccine , by Region Tons (2021-2026)
  • Table 668. Pneumococcal Vaccine Sales 23 - Valent Vaccine , by Region Tons (2021-2026)
  • Table 669. Pneumococcal Vaccine Sales: by Distribution Channel(Tons)
  • Table 670. Pneumococcal Vaccine Sales Non-Governmental Organizations , by Region Tons (2021-2026)
  • Table 671. Pneumococcal Vaccine Sales Governmental Organizations , by Region Tons (2021-2026)
  • Table 672. Pneumococcal Vaccine Sales: by Vaccine Type(Tons)
  • Table 673. Pneumococcal Vaccine Sales Synflorix , by Region Tons (2021-2026)
  • Table 674. Pneumococcal Vaccine Sales Prevnar 13 , by Region Tons (2021-2026)
  • Table 675. Pneumococcal Vaccine Sales Pneumovax 23 , by Region Tons (2021-2026)
  • Table 676. Pneumococcal Vaccine Sales: by End User(Tons)
  • Table 677. Pneumococcal Vaccine Sales Adults Above 65 Years , by Region Tons (2021-2026)
  • Table 678. Pneumococcal Vaccine Sales Children Above 2 Years , by Region Tons (2021-2026)
  • Table 679. South America Pneumococcal Vaccine Sales, by Country Tons (2021-2026)
  • Table 680. South America Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 681. South America Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 682. South America Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 683. South America Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 684. South America Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 685. South America Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 686. South America Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 687. Brazil Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 688. Brazil Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 689. Brazil Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 690. Brazil Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 691. Brazil Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 692. Brazil Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 693. Brazil Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 694. Argentina Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 695. Argentina Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 696. Argentina Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 697. Argentina Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 698. Argentina Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 699. Argentina Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 700. Argentina Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 701. Rest of South America Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 702. Rest of South America Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 703. Rest of South America Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 704. Rest of South America Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 705. Rest of South America Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 706. Rest of South America Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 707. Rest of South America Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 708. Asia Pacific Pneumococcal Vaccine Sales, by Country Tons (2021-2026)
  • Table 709. Asia Pacific Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 710. Asia Pacific Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 711. Asia Pacific Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 712. Asia Pacific Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 713. Asia Pacific Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 714. Asia Pacific Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 715. Asia Pacific Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 716. China Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 717. China Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 718. China Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 719. China Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 720. China Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 721. China Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 722. China Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 723. Japan Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 724. Japan Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
  • Table 725. Japan Pneumococcal Vaccine Sales, by Sector Type Tons (2021-2026)
  • Table 726. Japan Pneumococcal Vaccine Sales, by Vaccine Antigens Tons (2021-2026)
  • Table 727. Japan Pneumococcal Vaccine Sales, by Distribution Channel Tons (2021-2026)
  • Table 728. Japan Pneumococcal Vaccine Sales, by Vaccine Type Tons (2021-2026)
  • Table 729. Japan Pneumococcal Vaccine Sales, by End User Tons (2021-2026)
  • Table 730. India Pneumococcal Vaccine Sales, by Type Tons (2021-2026)
  • Table 731. India Pneumococcal Vaccine Sales, by Application Tons (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pneumococcal Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Pneumococcal Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Pneumococcal Vaccine: by Sector Type USD Million (2015-2020)
  • Figure 7. Global Pneumococcal Vaccine: by Vaccine Antigens USD Million (2015-2020)
  • Figure 8. Global Pneumococcal Vaccine: by Distribution Channel USD Million (2015-2020)
  • Figure 9. Global Pneumococcal Vaccine: by Vaccine Type USD Million (2015-2020)
  • Figure 10. Global Pneumococcal Vaccine: by End User USD Million (2015-2020)
  • Figure 11. South America Pneumococcal Vaccine Share (%), by Country
  • Figure 12. Asia Pacific Pneumococcal Vaccine Share (%), by Country
  • Figure 13. Europe Pneumococcal Vaccine Share (%), by Country
  • Figure 14. MEA Pneumococcal Vaccine Share (%), by Country
  • Figure 15. North America Pneumococcal Vaccine Share (%), by Country
  • Figure 16. Global Pneumococcal Vaccine: by Type Tons (2015-2020)
  • Figure 17. Global Pneumococcal Vaccine: by Application Tons (2015-2020)
  • Figure 18. Global Pneumococcal Vaccine: by Sector Type Tons (2015-2020)
  • Figure 19. Global Pneumococcal Vaccine: by Vaccine Antigens Tons (2015-2020)
  • Figure 20. Global Pneumococcal Vaccine: by Distribution Channel Tons (2015-2020)
  • Figure 21. Global Pneumococcal Vaccine: by Vaccine Type Tons (2015-2020)
  • Figure 22. Global Pneumococcal Vaccine: by End User Tons (2015-2020)
  • Figure 23. South America Pneumococcal Vaccine Share (%), by Country
  • Figure 24. Asia Pacific Pneumococcal Vaccine Share (%), by Country
  • Figure 25. Europe Pneumococcal Vaccine Share (%), by Country
  • Figure 26. MEA Pneumococcal Vaccine Share (%), by Country
  • Figure 27. North America Pneumococcal Vaccine Share (%), by Country
  • Figure 28. Global Pneumococcal Vaccine: by Type USD/Units (2015-2020)
  • Figure 29. Global Pneumococcal Vaccine share by Players 2020 (%)
  • Figure 30. Global Pneumococcal Vaccine share by Players (Top 3) 2020(%)
  • Figure 31. Global Pneumococcal Vaccine share by Players (Top 5) 2020(%)
  • Figure 32. BCG Matrix for key Companies
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi Pasteur (France) Revenue: by Geography 2020
  • Figure 43. Protein Sciences Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 44. Protein Sciences Corporation (United States) Revenue: by Geography 2020
  • Figure 45. Seqirus (United States) Revenue, Net Income and Gross profit
  • Figure 46. Seqirus (United States) Revenue: by Geography 2020
  • Figure 47. LG Chem Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 48. LG Chem Ltd. (South Korea) Revenue: by Geography 2020
  • Figure 49. Walvax Biotechnology Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 50. Walvax Biotechnology Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 51. Panacea Biotec (India) Revenue, Net Income and Gross profit
  • Figure 52. Panacea Biotec (India) Revenue: by Geography 2020
  • Figure 53. Pnuvax Incorporated (Canada) Revenue, Net Income and Gross profit
  • Figure 54. Pnuvax Incorporated (Canada) Revenue: by Geography 2020
  • Figure 55. Serum Institute of India Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 56. Serum Institute of India Pvt. Ltd. (India) Revenue: by Geography 2020
  • Figure 57. Global Pneumococcal Vaccine: by Type USD Million (2021-2026)
  • Figure 58. Global Pneumococcal Vaccine: by Application USD Million (2021-2026)
  • Figure 59. Global Pneumococcal Vaccine: by Sector Type USD Million (2021-2026)
  • Figure 60. Global Pneumococcal Vaccine: by Vaccine Antigens USD Million (2021-2026)
  • Figure 61. Global Pneumococcal Vaccine: by Distribution Channel USD Million (2021-2026)
  • Figure 62. Global Pneumococcal Vaccine: by Vaccine Type USD Million (2021-2026)
  • Figure 63. Global Pneumococcal Vaccine: by End User USD Million (2021-2026)
  • Figure 64. South America Pneumococcal Vaccine Share (%), by Country
  • Figure 65. Asia Pacific Pneumococcal Vaccine Share (%), by Country
  • Figure 66. Europe Pneumococcal Vaccine Share (%), by Country
  • Figure 67. MEA Pneumococcal Vaccine Share (%), by Country
  • Figure 68. North America Pneumococcal Vaccine Share (%), by Country
  • Figure 69. Global Pneumococcal Vaccine: by Type Tons (2021-2026)
  • Figure 70. Global Pneumococcal Vaccine: by Application Tons (2021-2026)
  • Figure 71. Global Pneumococcal Vaccine: by Sector Type Tons (2021-2026)
  • Figure 72. Global Pneumococcal Vaccine: by Vaccine Antigens Tons (2021-2026)
  • Figure 73. Global Pneumococcal Vaccine: by Distribution Channel Tons (2021-2026)
  • Figure 74. Global Pneumococcal Vaccine: by Vaccine Type Tons (2021-2026)
  • Figure 75. Global Pneumococcal Vaccine: by End User Tons (2021-2026)
  • Figure 76. South America Pneumococcal Vaccine Share (%), by Country
  • Figure 77. Asia Pacific Pneumococcal Vaccine Share (%), by Country
  • Figure 78. Europe Pneumococcal Vaccine Share (%), by Country
  • Figure 79. MEA Pneumococcal Vaccine Share (%), by Country
  • Figure 80. North America Pneumococcal Vaccine Share (%), by Country
  • Figure 81. Global Pneumococcal Vaccine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Novartis (Switzerland)
  • Pfizer Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Sanofi Pasteur (France)
  • Protein Sciences Corporation (United States)
  • Seqirus (United States)
  • LG Chem Ltd. (South Korea)
  • Walvax Biotechnology Co., Ltd. (China)
  • Panacea Biotec (India)
  • Pnuvax Incorporated (Canada)
  • Serum Institute of India Pvt. Ltd. (India)
Additional players considered in the study are as follows:
Beijing Minhai Biotechnology Corporation Limited (China) , SK Bioscience (South Korea)
Select User Access Type

Key Highlights of Report


Feb 2022 239 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pneumococcal Vaccine Quantitative research analysis
Global Pneumococcal Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Pneumococcal Vaccine market is expected to see a CAGR of 2.1% during projected year 2020 to 2026.
Top performing companies in the Global Pneumococcal Vaccine market are GlaxoSmithKline (United Kingdom), Novartis (Switzerland), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Sanofi Pasteur (France), Protein Sciences Corporation (United States), Seqirus (United States), LG Chem Ltd. (South Korea), Walvax Biotechnology Co., Ltd. (China), Panacea Biotec (India), Pnuvax Incorporated (Canada) and Serum Institute of India Pvt. Ltd. (India), to name a few.
Conjugate PCV13 is dominating segment of Pneumococcal Vaccine Market in 2020.

Know More About Global Pneumococcal Vaccine Report?

Have a Query? Click Here

Other Related Reports

Irinotecan Comprehensive Study by Type (Irinotecan Hydrochloride Injection 40mg, Irinotecan Hydrochloride Injection 100mg, Other), Application (Colon cancer, Rectal cancer), Route of Administration (...
$ 3500
Tobramycin Eye Drop Comprehensive Study by Type (Tobramycin and dexamethasone ophthalmic suspension, Tobramycin ophthalmic suspension, Other tobramycin Combination), Application (Adult, Children), En...
$ 3650
Policresulen Comprehensive Study by Type (Gels, Suppositories, Lotion, Implants, Soft Cream, Injection, Tablets, Capsule, Other), Application (Department Of Gynaecology, Surgery And Dermatology, Kouq...
$ 3650
mRNA Cancer Vaccines and Therapeutics Comprehensive Study by Type (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas), Application (Infectious Disease, Cancer, Others), End-users (Hospi...
$ 3500
Quercetin Dihydrate Comprehensive Study by Application (Atherosclerosis, Chronic Infections, Cosmetics, Nutraceuticals, Allergy & Inflammation, Others), Form (Powder, Solution), Distribution Channel ...
$ 3450
Calcium Supplement for Pets Comprehensive Study by Type (Tablets, Gel Cap, Powder, Liquid), Application (Dogs, Cats, Others), Distribution Channel (Online, Offline) Players and Region - Global Market...
$ 3800